Dariohealth Corp Financials
This page shows Dariohealth Corp (DRIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Dariohealth Corp has an operating margin of -245.5%, meaning the company retains $-246 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -213.5% the prior year.
Dariohealth Corp's revenue declined 44.8% year-over-year, from $27.0M to $14.9M. This contraction results in a growth score of 0/100.
With a current ratio of 3.76, Dariohealth Corp holds $3.76 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.
While Dariohealth Corp generated -$25.9M in operating cash flow, capex of $142K consumed most of it, leaving -$26.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Dariohealth Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Dariohealth Corp generates $0.62 in operating cash flow (-$25.9M OCF vs -$41.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Dariohealth Corp earns $-12.1 in operating income for every $1 of interest expense (-$36.7M vs $3.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Dariohealth Corp generated $14.9M in revenue in fiscal year 2025. This represents a decrease of 44.8% from the prior year.
Dariohealth Corp's EBITDA was -$33.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 33.4% from the prior year.
Dariohealth Corp reported -$41.7M in net income in fiscal year 2025. This represents an increase of 2.4% from the prior year.
Dariohealth Corp earned $10.12 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1559.0% from the prior year.
Cash & Balance Sheet
Dariohealth Corp generated -$26.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 32.6% from the prior year.
Dariohealth Corp held $21.8M in cash against $30.7M in long-term debt as of fiscal year 2025.
Dariohealth Corp had 7M shares outstanding in fiscal year 2025. This represents an increase of 280.3% from the prior year.
Margins & Returns
Dariohealth Corp's gross margin was 84.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 35.8 percentage points from the prior year.
Dariohealth Corp's operating margin was -245.5% in fiscal year 2025, reflecting core business profitability. This is down 32.0 percentage points from the prior year.
Dariohealth Corp's net profit margin was -279.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 121.3 percentage points from the prior year.
Capital Allocation
Dariohealth Corp invested $13.8M in research and development in fiscal year 2025. This represents a decrease of 43.0% from the prior year.
Dariohealth Corp invested $142K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2.9% from the prior year.
DRIO Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M-6.7% | $5.4M-20.5% | $6.8M-11.2% | $7.6M+2.4% | $7.4M+18.7% | $6.3M+8.6% | $5.8M+59.2% | $3.6M |
| Cost of Revenue | $2.0M-17.2% | $2.4M-16.2% | $2.9M-15.6% | $3.4M-4.1% | $3.5M+1.3% | $3.5M+5.2% | $3.3M-4.5% | $3.5M |
| Gross Profit | $3.0M+1.7% | $3.0M-23.6% | $3.9M-7.6% | $4.2M+8.4% | $3.9M+40.7% | $2.8M+13.3% | $2.4M+1742.4% | $132K |
| R&D Expenses | $3.3M-10.6% | $3.7M-9.4% | $4.1M-22.2% | $5.3M-3.0% | $5.4M-20.0% | $6.8M+2.5% | $6.6M+58.3% | $4.2M |
| SG&A Expenses | $4.6M+42.2% | $3.2M-3.0% | $3.3M-34.0% | $5.0M+34.5% | $3.7M-25.5% | $5.0M-25.7% | $6.7M+21.8% | $5.5M |
| Operating Income | -$9.5M-3.1% | -$9.2M+2.2% | -$9.4M+19.4% | -$11.7M+3.0% | -$12.0M+25.7% | -$16.2M+9.3% | -$17.9M-25.6% | -$14.2M |
| Interest Expense | $1.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | N/A | -$13K | N/A | $0 | N/A |
| Net Income | -$10.5M+19.4% | -$13.0M-40.8% | -$9.2M+4.2% | -$9.6M+21.9% | -$12.3M+9.4% | -$13.6M-89.7% | -$7.2M+49.8% | -$14.3M |
| EPS (Diluted) | $2.96 | $0.18+28.6% | $0.14 | N/A | $4.91+6037.5% | $0.08-60.0% | $0.20 | N/A |
DRIO Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $117.7M+8.7% | $108.3M-6.3% | $115.6M-2.8% | $118.9M+8.1% | $110.0M-10.0% | $122.1M-10.8% | $137.0M+42.1% | $96.4M |
| Current Assets | $42.2M+31.1% | $32.2M-16.6% | $38.6M-4.9% | $40.5M+37.3% | $29.5M-24.9% | $39.3M-25.1% | $52.5M+10.9% | $47.3M |
| Cash & Equivalents | $31.9M+45.3% | $22.0M-21.2% | $27.9M+0.3% | $27.8M+78.6% | $15.5M-32.2% | $22.9M-33.3% | $34.4M-6.6% | $36.8M |
| Inventory | $4.9M+5.6% | $4.6M-0.3% | $4.6M-2.8% | $4.8M+0.2% | $4.7M-7.6% | $5.1M+4.4% | $4.9M-2.9% | $5.1M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $57.4M0.0% | $57.4M0.0% | $57.4M0.0% | $57.4M0.0% | $57.4M0.0% | $57.4M0.0% | $57.4M+37.9% | $41.6M |
| Total Liabilities | $42.8M-3.5% | $44.3M+5.8% | $41.9M-10.6% | $46.9M-8.9% | $51.4M-4.9% | $54.1M-8.2% | $58.9M+54.1% | $38.2M |
| Current Liabilities | $9.3M-4.9% | $9.8M-49.1% | $19.2M+15.1% | $16.6M-11.7% | $18.8M+8.2% | $17.4M-2.2% | $17.8M+42.5% | $12.5M |
| Long-Term Debt | $30.6M+0.4% | $30.5M+61.4% | $18.9M-19.5% | $23.5M+16.3% | $20.2M-13.9% | $23.4M-4.4% | $24.5M-0.3% | $24.6M |
| Total Equity | $74.9M+17.1% | $64.0M-13.2% | $73.7M+2.3% | $72.0M+23.1% | $58.5M-14.0% | $68.1M-12.8% | $78.0M+34.2% | $58.1M |
| Retained Earnings | -$441.8M-4.5% | -$423.0M-4.6% | -$404.4M-3.6% | -$390.3M-3.2% | -$378.1M-4.0% | -$363.5M-1.4% | -$358.6M-2.6% | -$349.4M |
DRIO Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M-21.9% | -$6.0M+9.6% | -$6.7M+0.9% | -$6.7M+8.5% | -$7.4M+35.3% | -$11.4M+13.3% | -$13.1M-78.6% | -$7.3M |
| Capital Expenditures | $41K-6.8% | $44K+41.9% | $31K+47.6% | $21K-34.4% | $32K+10.3% | $29K-48.2% | $56K-32.5% | $83K |
| Free Cash Flow | -$7.4M-21.7% | -$6.1M+9.4% | -$6.7M+0.7% | -$6.8M+8.6% | -$7.4M+35.1% | -$11.4M+13.5% | -$13.2M-77.3% | -$7.4M |
| Investing Cash Flow | -$41K+6.8% | -$44K-41.9% | -$31K-47.6% | -$21K+34.4% | -$32K-10.3% | -$29K+99.7% | -$8.9M-10565.1% | -$83K |
| Financing Cash Flow | $17.4M+13926.6% | $124K-98.2% | $6.8M-62.8% | $18.3M | $0 | $0-100.0% | $20.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DRIO Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.2%+5.0pp | 55.2%-2.3pp | 57.5%+2.2pp | 55.3%+3.0pp | 52.2%+8.2pp | 44.1%+1.8pp | 42.2%+38.6pp | 3.6% |
| Operating Margin | -189.4%-18.1pp | -171.3%-32.0pp | -139.3%+14.1pp | -153.4%+8.6pp | -162.1%+96.8pp | -258.8%+51.2pp | -310.1%+83.0pp | -393.1% |
| Net Margin | -209.0%+32.9pp | -241.9%-105.3pp | -136.7%-10.0pp | -126.7%+39.4pp | -166.1%+51.5pp | -217.6%-93.0pp | -124.6%+270.4pp | -395.1% |
| Return on Equity | -14.0%+6.3pp | -20.3%-7.8pp | -12.5%+0.9pp | -13.4%+7.7pp | -21.1%-1.1pp | -20.0%-10.8pp | -9.2%+15.4pp | -24.6% |
| Return on Assets | -8.9%+3.1pp | -12.0%-4.0pp | -8.0%+0.1pp | -8.1%+3.1pp | -11.2%-0.1pp | -11.1%-5.9pp | -5.2%+9.6pp | -14.8% |
| Current Ratio | 4.55+1.2 | 3.30+1.3 | 2.01-0.4 | 2.44+0.9 | 1.57-0.7 | 2.26-0.7 | 2.95-0.8 | 3.79 |
| Debt-to-Equity | 0.41-0.1 | 0.48+0.2 | 0.26-0.1 | 0.33-0.0 | 0.340.0 | 0.34+0.0 | 0.31-0.1 | 0.42 |
| FCF Margin | -147.6%-34.5pp | -113.1%-13.9pp | -99.3%-10.5pp | -88.8%+10.7pp | -99.5%+82.6pp | -182.1%+46.5pp | -228.7%-23.3pp | -205.3% |
Note: Shareholder equity is negative ($0), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Dariohealth Corp's annual revenue?
Dariohealth Corp (DRIO) reported $14.9M in total revenue for fiscal year 2025. This represents a -44.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dariohealth Corp's revenue growing?
Dariohealth Corp (DRIO) revenue declined by 44.8% year-over-year, from $27.0M to $14.9M in fiscal year 2025.
Is Dariohealth Corp profitable?
No, Dariohealth Corp (DRIO) reported a net income of -$41.7M in fiscal year 2025, with a net profit margin of -279.4%.
What is Dariohealth Corp's EBITDA?
Dariohealth Corp (DRIO) had EBITDA of -$33.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Dariohealth Corp have?
As of fiscal year 2025, Dariohealth Corp (DRIO) had $21.8M in cash and equivalents against $30.7M in long-term debt.
What is Dariohealth Corp's gross margin?
Dariohealth Corp (DRIO) had a gross margin of 84.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Dariohealth Corp's operating margin?
Dariohealth Corp (DRIO) had an operating margin of -245.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Dariohealth Corp's net profit margin?
Dariohealth Corp (DRIO) had a net profit margin of -279.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Dariohealth Corp's free cash flow?
Dariohealth Corp (DRIO) generated -$26.1M in free cash flow during fiscal year 2025. This represents a 32.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Dariohealth Corp's operating cash flow?
Dariohealth Corp (DRIO) generated -$25.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Dariohealth Corp's total assets?
Dariohealth Corp (DRIO) had $110.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Dariohealth Corp's capital expenditures?
Dariohealth Corp (DRIO) invested $142K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Dariohealth Corp spend on research and development?
Dariohealth Corp (DRIO) invested $13.8M in research and development during fiscal year 2025.
What is Dariohealth Corp's current ratio?
Dariohealth Corp (DRIO) had a current ratio of 3.76 as of fiscal year 2025, which is generally considered healthy.
What is Dariohealth Corp's return on assets (ROA)?
Dariohealth Corp (DRIO) had a return on assets of -37.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Dariohealth Corp's cash runway?
Based on fiscal year 2025 data, Dariohealth Corp (DRIO) had $21.8M in cash against an annual operating cash burn of $25.9M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Dariohealth Corp's Piotroski F-Score?
Dariohealth Corp (DRIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dariohealth Corp's earnings high quality?
Dariohealth Corp (DRIO) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Dariohealth Corp cover its interest payments?
Dariohealth Corp (DRIO) has an interest coverage ratio of -12.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Dariohealth Corp?
Dariohealth Corp (DRIO) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.